Cancer

DeepScribe and Flatiron Health Announce Partnership To Bring Oncology-Specific Ambient AI to Flatiron’s 4,200+ Providers

DeepScribe to be the first ambient AI partner for Flatiron Health, integrating with their OncoEMR® to automatically document the complexities…

11 months ago

BIRD – Israel-U.S. Binational Industrial R&D Foundation to Invest $6 Million in 5 New Projects

The approved projects, with an overall budget of $15 million, involve innovations in Electronics, Healthcare, Medical Devices, and Quantum Computing…

11 months ago

CMS Doubles Down on Medicare Drug Price Controls, Threatening Patient Access and Innovation

ARLINGTON, VIRGINIA / ACCESS Newswire / January 22, 2025 / The Centers for Medicare & Medicaid Services (CMS) has announced…

11 months ago

Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies

Hamilton, Bermuda, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Exploring use of Altamira’s RNA nanoparticles in conjunction with radiopharmaceutical cancer treatment…

11 months ago

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Live webcast on Wednesday, January 29th at 2:40 PM ET PRINCETON, NJ, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics…

11 months ago

Biodexa Strengthens Management Team – Appointment of Dr Gary A. Shangold as Chief Medical Officer

January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC…

11 months ago

AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS

Recently published article on study findings underscores links between study participants infected with SARS-CoV-2 and the incidence of ME/CFS The…

11 months ago

Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers, Valued at Over $24.5 Million

CHICAGO, IL / ACCESS Newswire / January 22, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a…

11 months ago

Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain

Pain marks the second therapeutic area for Cullgen’s lead protein degrader CG001419SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Cullgen…

11 months ago